Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.76 |
| ▸ | HTR2A | P28223 | 9/20 | 0.76 |
| ▸ | HTR2C | P28335 | 9/20 | 0.76 |
| ▸ | HTR2B | P41595 | 9/20 | 0.76 |
| ▸ | DRD2 | P14416 | 4/20 | 0.66 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735882 | 0.89 | SIGMAR1 (0.63) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7307537 | 0.83 | SIGMAR1 (1.00) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7307527 | 0.83 | SIGMAR1 (1.00) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| Hydrochloric Acid SCHEMBL467373 | 0.82 | SIGMAR1 (0.97) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| Hydrochloric Acid SCHEMBL467375 | 0.82 | SIGMAR1 (0.97) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7312333 | 0.81 | SIGMAR1 (1.00) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7312324 | 0.81 | SIGMAR1 (1.00) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL430934 | 0.80 | IDO1 (0.68) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7514298 | 0.80 | IDO1 (0.68) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL430935 | 0.80 | IDO1 (0.68) | SIGMAR1HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308892-B2 | Di-cinnamyl compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8308892-B2 | Di-cinnamyl compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. | 2009-11-26 | — | — | US | disclosed |
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | CAD, DBF4, ACMSD | SIGMAR1 4142/4885HTR2A 4135/4885HTR2C 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.